MIT researchers published preclinical results showing a new class of degradable cyclic amino ionizable lipids and particle formulations that delivered influenza mRNA at roughly 1/100th the dose of current FDA‑approved LNP materials while achieving equivalent immune responses in mice. The work, published in Nature Nanotechnology, centers on AMG1541 and related ionizable lipids screened through combinatorial libraries. A separate MIT team reported complementary findings identifying particle features that improve endosomal escape and potency, suggesting a reproducible design path to lower dose requirements and potentially reduce reactogenicity and cost per dose. The studies used luciferase reporters and influenza antigen models to benchmark performance across delivery chemistries. If the potency and safety profile translate in larger animal models and humans, these discoveries could materially reduce mRNA vaccine manufacturing costs and supply constraints, and influence LNP selection for therapeutic mRNAs beyond vaccines.